Symbiosis Pharmaceutical Services has launched new in-house analytical and microbiological capabilities to enable testing of small molecule, biological, and Advanced Therapeutic Medicinal Products (ATMP) biopharmaceuticals following a $1.25 million investment. The company has added 3,600 ft² of new space, significantly expanding its existing GMP operational footprint at the Stirling Innovation Park site in Scotland.    Fully approved by the UK Regulatory Agency the MHRA, the expansion strategi...